Platelet-activating factor receptor antagonist BN 52021 in the treatment of severe sepsis: A randomized, double-blind, placebo-controlled, multicenter clinical trial

Platelet Activating Factor Receptor

Double Blind ◽

Double Blind Placebo ◽

Platelet-activating factor receptor antagonist BN 52021 in the treatment of severe sepsis: A randomized, double-blind, placebo-controlled, multicenter clinical trial

Critical Care Medicine ◽

10.1097/00003246-199422110-00005 ◽

1994 ◽

Vol 22 (11) ◽

pp. 1720-1728 ◽

Cited By ~ 187

Author(s):

Jean-Francois A. Dhainaut ◽

Alain Tenaillon ◽

Yves Le Tulzo ◽

Benoit Schlemmer ◽

Jean-Pierre Solet ◽

...

Keyword(s):

Clinical Trial ◽

Severe Sepsis ◽

Receptor Antagonist ◽

Platelet Activating Factor Receptor

Double Blind ◽

Double Blind Placebo ◽

Recombinant human platelet-activating factor acetylhydrolase for treatment of severe sepsis: Results of a phase III, multicenter, randomized, double-blind, placebo-controlled, clinical trial*

Critical Care Medicine ◽

10.1097/01.ccm.0000108867.87890.6d ◽

2004 ◽

Vol 32 (2) ◽

pp. 332-341 ◽

Cited By ~ 113

Author(s):

Steven Opal ◽

Pierre-Francois Laterre ◽

Edward Abraham ◽

Bruno Francois ◽

Xavier Wittebole ◽

...

Keyword(s):

Clinical Trial ◽

Severe Sepsis ◽

Human Platelet ◽

Platelet Activating Factor Acetylhydrolase

Phase Iii ◽

Controlled Clinical Trial ◽

Double Blind ◽

Double Blind Placebo ◽

Faculty Opinions recommendation of Adenosine A2A receptor antagonist istradefylline (KW-6002) reduces "off" time in Parkinson's disease: a double-blind, randomized, multicenter clinical trial (6002-US-005).

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1119107.577195 ◽

2008 ◽

Author(s):

Stewart Factor

Keyword(s):

Parkinson’S Disease ◽

Clinical Trial ◽

Receptor Antagonist ◽

Adenosine A2a Receptor ◽

Double Blind ◽

A2a Receptor ◽

Adenosine A2a Receptor Antagonist ◽

Adenosine A2a ◽

Off Time

Vitamin A treatment for severe sepsis in humans; a prospective randomized double blind placebo-controlled clinical trial

Clinical Nutrition ESPEN ◽

10.1016/j.clnesp.2018.10.011 ◽

2019 ◽

Vol 29 ◽

pp. 49-51 ◽

Cited By ~ 2

Author(s):

Lavanya Cherukuri ◽

Gail Gewirtz ◽

Kea Osea ◽

John A. Tayek

Keyword(s):

Clinical Trial ◽

Severe Sepsis ◽

Vitamin A ◽

Controlled Clinical Trial ◽

Double Blind ◽

A randomized, double-blind, placebo-controlled, multicenter clinical trial for efficacy and safety of traditional Chinese medicine combined with antibiotics in the treatment of bacterial pneumonia in children

Medicine ◽

10.1097/md.0000000000023217 ◽

2020 ◽

Vol 99 (50) ◽

pp. e23217

Author(s):

Lina Wei ◽

Yina Guo ◽

Yutong Fei ◽

Lin Luo ◽

Caiwen Wang ◽

...

Keyword(s):

Clinical Trial ◽

Chinese Medicine ◽

Traditional Chinese Medicine ◽

Bacterial Pneumonia ◽

Efficacy And Safety ◽

Double Blind ◽

AB0629 Design of A Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial of The Toll-like Receptor Antagonist IMO-8400 in Patients with Dermatomyositis

Annals of the Rheumatic Diseases ◽

10.1136/annrheumdis-2016-eular.5174 ◽

2016 ◽

Vol 75 (Suppl 2) ◽

pp. 1119.2-1119 ◽

Cited By ~ 2

Author(s):

P. Gordon ◽

R. Cooper ◽

H. Chinoy ◽

D. Isenberg ◽

I.E. Lundberg ◽

...

Keyword(s):

Clinical Trial ◽

Receptor Antagonist ◽

Phase 2 ◽

Toll Like Receptor ◽

Double Blind ◽

Double Blind Placebo ◽

Phase 2 Clinical Trial

Sodium oxybate relieves pain and improves function in fibromyalgia syndrome: A randomized, double-blind, placebo-controlled, multicenter clinical trial

Arthritis & Rheumatism ◽

10.1002/art.24142 ◽

2009 ◽

Vol 60 (1) ◽

pp. 299-309 ◽

Cited By ~ 95

Author(s):

I. Jon Russell ◽

A. Thomas Perkins ◽

Joel E. Michalek ◽

Keyword(s):

Clinical Trial ◽

Fibromyalgia Syndrome ◽

Sodium Oxybate ◽

Double Blind ◽

China Tongxinluo Study for myocardial protection in patients with Acute Myocardial Infarction (CTS-AMI): Rationale and design of a randomized, double-blind, placebo-controlled, multicenter clinical trial

American Heart Journal ◽

10.1016/j.ahj.2020.06.011 ◽

2020 ◽

Vol 227 ◽

pp. 47-55

Author(s):

Yi Xu ◽

Xiangdong Li ◽

Haitao Zhang ◽

Yuan Wu ◽

Jun Zhang ◽

...

Keyword(s):

Myocardial Infarction ◽

Acute Myocardial Infarction ◽

Clinical Trial ◽

Myocardial Protection ◽

Double Blind ◽

Efficacy and Safety of the Platelet-Activating Factor Receptor Antagonist BN???52021 (Ginkgolide??B) in Patients with Severe Sepsis

Clinical Drug Investigation ◽

10.2165/00044011-200424030-00002 ◽

2004 ◽

Vol 24 (3) ◽

pp. 137-147 ◽

Cited By ~ 5

Author(s):

D M Albrecht ◽

K van Ackern ◽

H -J Bender ◽

H Hof ◽

W Kox ◽

...

Keyword(s):

Severe Sepsis ◽

Receptor Antagonist ◽

Platelet Activating Factor Receptor

Ginkgolide B ◽

Efficacy And Safety ◽

Faculty Opinions recommendation of EMA401, an orally administered highly selective angiotensin II type 2 receptor antagonist, as a novel treatment for postherpetic neuralgia: a randomised, double-blind, placebo-controlled phase 2 clinical trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718270683.793501691 ◽

2014 ◽

Author(s):

Nanna Finnerup

Keyword(s):

Clinical Trial ◽

Angiotensin Ii ◽

Receptor Antagonist ◽

Postherpetic Neuralgia ◽

Phase 2 ◽

Double Blind ◽

Double Blind Placebo ◽

Novel Treatment ◽

Phase 2 Clinical Trial